Cyclerion Therapeutics Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.4yrs

Jüngste Management Updates

Recent updates

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 26

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Jun 21

Cyclerion climbs on a series of insider purchases

Jun 08

Cyclerion updates on clinical trial progress at webinar

Apr 28

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Mar 09

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Jan 28

Cyclerion Therapeutics +10.5% after prelim reports

Jan 13

Cyclerion Therapeutics announces promotions

Dec 21

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Dec 20

Cyclerion Therapeutics reports Q3 results

Nov 05

Geschäftsführer

Cyclerion Therapeutics hat keinen Geschäftsführer, oder es liegen keine verfügbaren Daten vor.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Terrance McGuire	Independent Director	5.2yrs	US$27.60k	0.24% $ 16.0k
Peter Hecht	Director	5.2yrs	US$169.80k	15.1% $ 1.0m
Errol De Souza	Independent Chairman	3.2yrs	US$131.08k	2% $ 135.8k
Steven Hyman	Independent Director	1.9yrs	US$57.30k	0.80% $ 54.3k
Michael Higgins	Independent Director	less than a year	US$43.60k	0.80% $ 54.3k
Robert Malenka	Member of Scientific Advisory Board	3.4yrs	keine Daten	keine Daten
Daniela Salvemini	Member of Scientific Advisory Board	3.4yrs	keine Daten	keine Daten
Mark Currie	Chair of Scientific Advisory Board	no data	US$366.78k	keine Daten
Andrew Budson	Member of Clinical Advisory Board	3.4yrs	keine Daten	keine Daten
Eric Smith	Member of Clinical Advisory Board	3.4yrs	keine Daten	keine Daten
M Westover	Member of Clinical Advisory Board	3.4yrs	keine Daten	keine Daten
David Salat	Member of Clinical Advisory Board	3.4yrs	keine Daten	keine Daten

3.4yrs

Durchschnittliche Betriebszugehörigkeit

68.5yo

Durchschnittliches Alter

Erfahrener Vorstand: CYCNDie Vorstandsmitglieder gelten als erfahren (3.4 Jahre durchschnittliche Amtszeit).

Cyclerion Therapeutics Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Cyclerion Therapeutics, Inc., Annual General Meeting, Jun 14, 2024

Cyclerion Therapeutics, Inc. Appoints Regina Graul as President

Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments

Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director

Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer

High number of new and inexperienced directors

Recent updates

Cyclerion Therapeutics, Inc., Annual General Meeting, Jun 14, 2024

Cyclerion Therapeutics, Inc. Appoints Regina Graul as President

Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments

Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director

Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer

New major risk - Financial position

First half 2023 earnings released: US$5.00 loss per share (vs US$12.14 loss in 1H 2022)

New major risk - Market cap size

Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding

High number of new and inexperienced directors

J & W Cycles, Inc. signed a definitive agreement to acquire sGC Stimulator Assets of Cyclerion Therapeutics, Inc. for $8 million.

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.30 loss in 1Q 2022)

Full year 2022 earnings released: US$1.01 loss per share (vs US$1.32 loss in FY 2021)

Cyclerion Therapeutics Announces an Extended Listing Compliance Period

Price target decreased to US$4.00

Third quarter 2022 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021)

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Consensus revenue estimates fall by 54%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia

Cyclerion Therapeutics, Inc. Announces Appointment of Steven E. Hyman, M.D., to its Board of Directors

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Cyclerion Therapeutics, Inc. Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for Cy6463 in Melas Patients At Umdf Mitochondrial Medicine 2022 Symposium

Cyclerion Therapeutics Receives a Deficiency Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price Requirement

High number of new directors

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cyclerion Therapeutics, Inc. Announces CY6463 Clinical Pipeline Progress

Price target increased to US$10.50

High number of new directors

Consensus revenue estimates fall by 49%

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Full year 2021 earnings: EPS and revenues miss analyst expectations

Cyclerion Therapeutics, Inc. Announces CY6463 Clinical Pipeline Updates

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology

Third quarter 2021 earnings released: US$0.26 loss per share (vs US$0.59 loss in 3Q 2020)

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Cyclerion Therapeutics, Inc Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Independent Director Kevin Churchwell has left the company

Second quarter 2021 earnings released: US$0.45 loss per share (vs US$0.70 loss in 2Q 2020)

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021

Cyclerion Therapeutics, Inc.(NasdaqGS:CYCN) dropped from Russell 3000E Value Index

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Cyclerion climbs on a series of insider purchases

Cyclerion Therapeutics, Inc. announced that it has received $17.896283 million in funding from EcoR1 Capital, LLC, Slate Path Capital LP, MFN Partners Management, LP, The Invus Group, LLC, Lincoln Park Capital, LLC, Polaris Partners

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

CEO & Director recently bought US$1.7m worth of stock

First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.73 loss in 1Q 2020)

Cyclerion Therapeutics, Inc. Provides Clinical Updates for its CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 in Alzheimer's Disease with Vascular Pathology and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes

Cyclerion updates on clinical trial progress at webinar

Cyclerion Therapeutics, Inc. Announces Departure of Christopher Wright as Chief Medical Officer

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Full year 2020 earnings released: US$2.56 loss per share (vs US$4.49 loss in FY 2019)

Earnings beat expectations

New 90-day high: US$3.61

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards

New 90-day high: US$3.60

Cyclerion Therapeutics +10.5% after prelim reports

President & Chief Scientific Officer notifies of intention to sell stock

President & Chief Scientific Officer recently sold US$61k worth of stock

Cyclerion Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective January 1, 2021

Cyclerion Therapeutics announces promotions

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Chief Innovation Officer recently bought US$316k worth of stock

Third quarter 2020 earnings released: US$0.59 loss per share

Revenue and earnings beat expectations